Yestar Healthcare Issues Supplemental Announcement on Equipment Acquisition for Advanced Materials Production

Key Points for Investors

• Discloseable Transactions: Yestar Healthcare Holdings Company Limited (“Yestar Healthcare” or “the Company”) has issued a supplemental announcement regarding the acquisition of equipment for the production of advanced materials.
• Valuation of Equipment: The acquisition price for the production and main equipment was set after arm’s length negotiation and is confirmed by an independent valuer, Beijing Yingyue Asset Appraisal Co., Ltd. The appraised value is approximately RMB55,880,000 (about US\$7,871,000) as of 15 October 2025.
• Valuation Methodology: The independent valuer used the cost approach due to the specialized, custom-made nature of the equipment and uncertainty about future income, rather than market or income approaches.
• Valuation Inputs and Assumptions: Replacement costs were calculated by considering recent purchase prices, logistics, insurance, installation, commission, and other fees, minus depreciation. Key assumptions include stable laws, no major macroeconomic or financial upheavals, and acquisition of all necessary licenses.
• Delivery Timeline: Equipment will be delivered within 4 months of payment receipt. The timeline accounts for disassembly, export license application from the Dutch government, and logistics from the Netherlands.
• Vendor Information: The vendor is ultimately owned by Mr. Ho Tony, who is confirmed as an Independent Third Party.
• Board’s Position: The Board believes the valuation and delivery schedule are fair and reasonable, and the acquisition is in the best interests of the Group and shareholders.
• Validity of Valuation: The equipment valuation remains valid for one year from 15 October 2025 to 14 October 2026. A new valuation will be required after this period.
• Monitoring Mechanisms: The Company is actively monitoring delivery progress, including regular updates on export license approval and shipment tracking.

Potentially Price Sensitive Information for Shareholders

• Significant Capital Outlay: The acquisition of specialized production equipment valued at nearly RMB56 million represents a substantial investment for Yestar Healthcare. This could impact the Company’s cash flow and future earnings, depending on how these assets are utilized.
• Strategic Expansion: The equipment is intended for advanced materials production, suggesting a strategic move into new or expanded manufacturing capabilities, which may influence the Company’s future growth prospects and market positioning.
• Delivery Risks: The delivery timeline is contingent on obtaining an export license from the Dutch government. Any delays or regulatory issues could impact project execution, potentially affecting future revenues and profitability.
• Valuation Validity and Uncertainty: The valuation is only valid for one year, and future asset value may be affected by macroeconomic conditions, regulatory changes, or other unforeseen events.
• Vendor Independence: Confirmation that the vendor and its owner are independent from the Company reduces related party risk, which can be a concern for investors.
• Exchange Rate Sensitivity: The valuation uses a fixed exchange rate for illustrative purposes; actual rates may differ and could impact the effective cost in RMB or US dollars.

Detailed Analysis

Yestar Healthcare has taken a transparent approach in disclosing the methodology and assumptions underlying the valuation of the newly acquired production and main equipment. The assets are custom-made and imported, primarily from the Netherlands, and are brand-new and unused. The cost approach was chosen for valuation due to the absence of a liquid secondary market and uncertainty around future income potential from these assets.

The replacement cost calculation considered a comprehensive array of factors, including FOB prices from the vendor, ocean freight, insurance, domestic handling, foundation, installation, commissioning, bank finance charges, trade handling fees, and capital costs. Depreciation was minimal, given the newness of the assets.

The delivery period of 4 months is justified by the complexity and bulkiness of the equipment, the need for disassembly, full payment prior to shipment, and the requirement for an export license from Dutch authorities. The Company is actively monitoring progress, aiming to safeguard shareholder interests.

The Board explicitly states that the valuation, delivery schedule, and acquisition terms are fair, reasonable, and in the interests of shareholders and the Group. This is a positive signal for investor confidence.

The vendor is owned by Mr. Ho Tony, who is confirmed to be an independent third party, mitigating any concerns about potential conflicts of interest.

Finally, the valuation is valid for one year, after which a new assessment will be required. The Company has provided a currency conversion rate (US\$1.00 = RMB7.0995) for illustration purposes, cautioning that actual rates may vary.

Conclusion

The acquisition and its transparent disclosure may be viewed positively by investors as it signals a strategic investment in advanced manufacturing capabilities. However, the significant capital outlay, delivery risks, and the one-year limitation on valuation validity are factors that shareholders should monitor closely. Any delays or unforeseen changes in macroeconomic or regulatory environments could have an impact on the Company’s financials and share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information herein is based on the supplemental announcement from Yestar Healthcare Holdings Company Limited and may be subject to change. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.

View YESTAR HEALTH Historical chart here